Skip to main content
Cube Labs S.p.A. logo

Cube Labs S.p.A. — Investor Relations & Filings

Ticker · CUBE ISIN · IT0005532483 LEI · 815600566D45248BEB28 XMIL Professional, scientific and technical activities
Open in API
Filings indexed 131 across all filing types
Latest filing 2023-12-21 Share Issue/Capital Cha…
Country IT Italy
Listing XMIL CUBE

About Cube Labs S.p.A.

https://cube-labs.com/

Cube Labs S.p.A. is a venture builder specializing in the healthcare technology and life sciences sectors. The company's model focuses on identifying promising academic research and development and transforming it into commercial enterprises. It creates and nurtures startups to bridge the gap between scientific discovery and market-ready healthcare solutions. The firm's investment and development activities cover key areas including pharmaceuticals, biotechnology, medical technology (MedTech), nutraceuticals, and the application of artificial intelligence in R&D. A core part of its mission is to make research, technologies, and tools more accessible, fostering open innovation and collaboration to accelerate the development of new healthcare technologies.

Recent filings

Filing Released Lang Actions
AVVIO COLLOCAMENTO DI AZIONI RISERVATO A INVESTITORI QUALIFICATI
Share Issue/Capital Change Classification · 99% confidence The document is titled 'AVVIO COLLOCAMENTO DI AZIONI RISERVATO A INVESTITORI QUALIFICATI' (Start of Share Placement Reserved for Qualified Investors) and explicitly states that the Board of Directors resolved to proceed with the placement of up to 250,000 new shares for a maximum value of EUR 500,000. This action involves raising capital through the issuance of new shares, which directly corresponds to the definition of a Capital/Financing Update (CAP). Although it involves shares, it is a financing activity rather than a routine share repurchase (POS) or a general capital change announcement (SHA), as the primary purpose is fundraising via a placement. It is a formal announcement, not a short notice of publication, so RPA/RNS is less appropriate than the specific financing code.
2023-12-21 Italian
CUBE LABS AMPLIA IL PORTAFOGLIO PARTECIPAZIONI CON DUE NUOVE STARTUP NELLA NUTRACEUTICA E NEL MEDTECH
M&A Activity Classification · 99% confidence The document is a formal communication titled 'Informazione Regolamentata' (Regulated Information) from CUBE LABS, dated December 6, 2023. The subject ('Oggetto') is 'PARTECIPAZIONI CON DUE NUOVE STARTUP NELLA NUTRACEUTICA E NEL MEDTECH' (Holdings with two new startups in Nutraceuticals and MedTech). The text details the creation of two new subsidiary companies and Cube Labs' investment plan. This type of announcement, which details corporate actions, investments, or significant business developments outside of routine financial reporting (like 10-K or ER), often falls under general regulatory announcements or specific corporate action categories. Since it is not a standard financial report (10-K, IR, ER, MRQ), nor a management change (MANG), nor a dividend notice (DIV), nor a capital change (SHA/CAP), it best fits the general category for significant, non-standard regulatory disclosures. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a specific, material corporate announcement that doesn't fit a more precise category like M&A (TAR) or Director's Dealing (DIRS). It is a formal press release/regulatory notice.
2023-12-06 Italian
CUBE LABS: COMUNICAZIONE DI VARIAZIONE DEL CAPITALE SOCIALE
Share Issue/Capital Change Classification · 99% confidence The document is titled 'CUBE LABS: COMUNICAZIONE DI VARIAZIONE DEL CAPITALE SOCIALE' (Communication of Share Capital Variation). It explicitly details the issuance of new shares following the exercise of warrants, resulting in a change to the total number of shares and the total subscribed capital. This directly relates to changes in the company's capital structure. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it concerns a specific capital event.
2023-11-14 Italian
WARRANT CUBE LABS 2023 – 2025 RISULTATI DEL PRIMO PERIODO DI ESERCIZIO 9-20 OTTOBRE 2023
Share Issue/Capital Change Classification · 99% confidence The document is an official communication titled 'WARRANT CUBE LABS 2023 – 2025 RISULTATI DEL PRIMO PERIODO DI ESERCIZIO 9-20 OTTOBRE 2023' (Results of the First Exercise Period). It details the exercise of warrants, the subsequent subscription of new shares, and the resulting change in the company's share capital. This activity directly relates to changes in the company's capital structure and financing instruments. This fits best under the 'Capital/Financing Update' category (CAP), as it is a specific announcement about the execution of a capital event (warrant exercise leading to share issuance). Although it is a press release, the core subject matter is capital change, making CAP more specific than the general 'RPA' or 'RNS'. The document length is substantial enough (6061 chars) that it is the report itself, not just an announcement of a report.
2023-10-23 Italian
APERTURA DEL PRIMO PERIODO DI ESERCIZIO “WARRANT CUBE LABS 2023 – 2025”
Share Issue/Capital Change Classification · 99% confidence The document is an official announcement (Informazione Regolamentata) from Cube Labs regarding the opening of the first subscription period for its 'Warrant Cube Labs 2023 – 2025'. This announcement details the terms, dates (October 9 to October 20, 2023), and exercise price (€2.00) for converting warrants into new ordinary shares. This activity directly relates to the company's capital structure and financing instruments, specifically the issuance/exercise of warrants. This fits best under the 'Capital/Financing Update' category (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it concerns a specific corporate finance event.
2023-10-06 Italian
RICHIAMO INFORMATIVA
Audit Report / Information Classification · 99% confidence The document is an official communication (Comunicato Stampa) dated September 29, 2023, which explicitly states that it is informing the market about the 'Relazione della Società di Revisione sulla Relazione Finanziaria Semestrale al 30 giugno 2023' (Auditor's Report on the Half-Year Financial Report as of June 30, 2023). The text includes the full 'Relazione di revisione contabile limitata sulla relazione semestrale' (Limited review report on the half-year financial report) issued by Ria Grant Thornton S.p.A. This document is the formal audit/review report pertaining to an interim financial statement, not the full annual report (10-K) or the initial earnings release (ER). The definition for Audit Report / Information (AR) covers 'Standalone audit reports, applied accounting principles, and results of internal or regulatory stress tests (excluding full Annual Reports)'. Since this is a limited review report on a semi-annual financial statement, AR is the most appropriate classification, as it is a specific audit-related document for an interim period. H1 2023
2023-09-29 Italian

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.